Capital Must Deploy, But Buyers Won't Overpay — M&A's Dry Powder Dilemma in 2026.

Private equity in 2026 faces a strange contradiction. Firms are sitting on historically high levels of undeployed capital, yet many sponsors remain reluctant buyers. On the surface, these facts appear incompatible, but in reality they reflect two forces pushing in opposite directions. In issue three, we discussed how deal value is increasing asymmetrically to deal volume — this is a notable side effect of the structural dynamic.

The KPMG 2026 M&A Deal Market Study, which surveyed 150 PE and 150 corporate dealmakers, found that 43% of PE dealmakers describe their primary strategy for deploying dry powder in 2026 is maintaining price discipline, even at the cost of slower deployment. KPMG calls this an optimistic but intentional approach.

It isn't pessimism. Sponsors have watched many 2021-vintage deals struggle and concluded that the bigger risk is buying the wrong asset for the wrong price, not deploying capital too slowly.

The same study found that a majority of those same firms want a 100–150 basis point rate cut before they meaningfully start ramping up activity. Similar findings were produced from KPMG's contemporaries. BDO's 2026 predictions describe disciplined GPs focusing on pricing, operational value creation levers, and selective deployment in sectors with durable fundamentals. Ocorian's private capital outlook labels the prevailing sentiment as "tempered optimism".

On the other side of the equation, US private equity is holding roughly $1 trillion in committed-but-undeployed capital, per EdgePoint's February 2026 estimate. Pitchbook's data shows that about 50% of dry powder sits in funds between two and five years old — largely similar to the previous quarter.

The reason the length of time the capital is held matters is because most firms operate on defined investment periods. There is a finite limit on how long they can continue calling capital. Money committed in 2022 and 2023 has a deadline, and this is why several forecasters expect deployment to accelerate regardless of where rates land. As investment periods mature, GPs face increasing pressure to either deploy capital or release it unused — an outcome few will find desirable.

So which force wins? From what we're seeing, neither is cleanly winning. Instead, the data is showing that deal value continues to rise while deal volume stays relatively flat. Rather than forcing capital into numerous smaller transactions, firms are making their bets on larger, higher-conviction deals. Sponsors are deploying because if they don't they'll lose out, and they're being more selective because if they don't they'll get burned.

A market where capital must deploy but buyers refuse to overpay concentrates activity into fewer, higher-conviction deals. For M&A professionals, this raises the value of judgement. That means screening effectively, underwriting quality quickly, and pricing with discipline when the deployment clock is pushing the other way.